Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERE Cerevel Therapeutics	$44.96	$43.67	$19.59 ▼ $44.99	$8.19B	1.4	1.71 million shs	N/A
CNR Core Natural Resources	$76.14 +0.3%	$72.66	$58.19 ▼ $134.59	$3.91B	0.66	845,461 shs	747,755 shs
CNX CNX Resources	$29.08 +0.1%	$32.28	$25.68 ▼ $41.93	$4.11B	0.64	2.58 million shs	1.23 million shs
HCC Warrior Met Coal	$60.72 +1.7%	$49.87	$38.00 ▼ $75.15	$3.14B	0.69	1.25 million shs	1.25 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERE Cerevel Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
CNR Core Natural Resources	+0.36%	+4.63%	+10.12%	+13.76%	-41.65%
CNX CNX Resources	+0.11%	+0.55%	-10.47%	-7.15%	+18.21%
HCC Warrior Met Coal	+1.66%	+17.93%	+24.04%	+34.34%	+2.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CERE Cerevel Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNR Core Natural Resources	3.8622 of 5 stars	3.4	0.0	1.7	1.5	3.9	1.7	2.5
CNX CNX Resources	3.9321 of 5 stars	1.8	2.0	0.0	0.0	3.5	3.3	3.8
HCC Warrior Met Coal	2.9478 of 5 stars	1.2	3.0	1.7	0.0	3.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERE Cerevel Therapeutics	0.00	N/A	N/A	N/A
CNR Core Natural Resources	2.80	Moderate Buy	$105.80	38.95% Upside
CNX CNX Resources	1.63	Reduce	$31.92	9.78% Upside
HCC Warrior Met Coal	2.40	Hold	$61.00	0.46% Upside

Current Analyst Ratings Breakdown

Latest CERE, CNR, CNX, and HCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CNR Core Natural Resources	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $86.00
8/7/2025	HCC Warrior Met Coal	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Market Perform	$50.00 ➝ $55.00
8/5/2025	CNR Core Natural Resources	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$67.00 ➝ $78.00
8/1/2025	CNX CNX Resources	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$25.00 ➝ $26.00
7/22/2025	CNR Core Natural Resources	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$112.00 ➝ $110.00
7/22/2025	HCC Warrior Met Coal	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$76.00 ➝ $74.00
7/11/2025	CNX CNX Resources	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$33.00 ➝ $35.00
7/7/2025	CNX CNX Resources	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/7/2025	CNX CNX Resources	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$33.00
7/3/2025	CNR Core Natural Resources	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
6/11/2025	CNR Core Natural Resources	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERE Cerevel Therapeutics	N/A	N/A	N/A	N/A	$3.71 per share	N/A
CNR Core Natural Resources	$2.24B	1.75	$19.57 per share	3.89	$73.20 per share	1.04
CNX CNX Resources	$1.27B	3.25	$5.24 per share	5.55	$28.94 per share	1.00
HCC Warrior Met Coal	$1.53B	2.09	$8.14 per share	7.46	$39.57 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERE Cerevel Therapeutics	-$432.84M	-$2.73	N/A	N/A	N/A	N/A	-98.94%	-45.07%	N/A
CNR Core Natural Resources	$286.40M	$2.18	34.93	4.33	N/A	0.63%	3.01%	1.78%	N/A
CNX CNX Resources	-$90.49M	$0.59	49.29	10.81	0.25	9.70%	8.93%	4.13%	10/23/2025 (Estimated)
HCC Warrior Met Coal	$250.60M	$2.01	78.86	6.78	N/A	3.30%	2.26%	1.81%	N/A

Latest CERE, CNR, CNX, and HCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	HCC Warrior Met Coal	-$0.28	$0.11	+$0.39	$0.11	$285.63 million	$297.52 million
8/5/2025	Q2 2025	CNR Core Natural Resources	$1.31	-$0.70	-$2.01	-$0.70	$1.04 billion	$1.10 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERE Cerevel Therapeutics	N/A	N/A	N/A	N/A	N/A
CNR Core Natural Resources	$0.40	0.53%	N/A	18.35%	N/A
CNX CNX Resources	N/A	N/A	N/A	N/A	N/A
HCC Warrior Met Coal	$0.32	0.53%	N/A	15.92%	1 Years

Latest CERE, CNR, CNX, and HCC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	HCC Warrior Met Coal	quarterly	$0.08	0.6%	8/8/2025	8/8/2025	8/15/2025
5/24/2025	CNR Core Natural Resources		$0.10	0.57%	5/30/2025	6/2/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERE Cerevel Therapeutics	0.60	10.22	10.22
CNR Core Natural Resources	0.09	1.78	1.34
CNX CNX Resources	0.56	0.33	0.30
HCC Warrior Met Coal	0.12	4.59	4.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERE Cerevel Therapeutics	87.73%
CNR Core Natural Resources	86.54%
CNX CNX Resources	95.16%
HCC Warrior Met Coal	92.28%

Insider Ownership

Company	Insider Ownership
CERE Cerevel Therapeutics	5.10%
CNR Core Natural Resources	1.41%
CNX CNX Resources	3.10%
HCC Warrior Met Coal	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERE Cerevel Therapeutics	300	182.20 million	172.90 million	Optionable
CNR Core Natural Resources	2,076	51.47 million	50.75 million	Optionable
CNX CNX Resources	470	141.42 million	137.04 million	Optionable
HCC Warrior Met Coal	1,336	52.57 million	51.46 million	Optionable

CERE, CNR, CNX, and HCC Headlines

Recent News About These Companies

Warrior Met Coal (NYSE:HCC) Price Target Raised to $55.00

August 8 at 8:41 AM | marketbeat.com

Warrior Met Coal (HCC) Q2 EPS Beats View

August 7 at 9:02 AM | theglobeandmail.com

Warrior Met Coal accelerates Blue Creek longwall startup to early Q1 2026 while expanding Asian sales share

August 7 at 9:02 AM | msn.com

Warrior Met Coal (HCC) Reports Lower Earnings Amid Market Pressures

August 7 at 7:50 AM | gurufocus.com

Warrior Met Coal, Inc. (HCC) Q2 2025 Earnings Call Transcript

August 7 at 7:01 AM | seekingalpha.com

Warrior Met Coal Reports Q2 2025 Earnings

August 7 at 4:02 AM | msn.com

Decoding Warrior Met Coal Inc (HCC): A Strategic SWOT Insight

August 6 at 12:39 AM | gurufocus.com

Warrior Met Coal, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 6 at 8:46 PM | seekingalpha.com

Warrior Met Coal (HCC) Tops Q2 Earnings and Revenue Estimates

August 6 at 6:40 PM | zacks.com

Warrior Met Coal Inc (HCC) Q2 2025 Earnings: EPS of $0.11 Beats Estimate, Revenue Hits $297. ...

August 6 at 5:13 PM | gurufocus.com

Warrior Reports Second Quarter 2025 Results and Updates Outlook

August 6 at 5:13 PM | gurufocus.com

Warrior Reports Second Quarter 2025 Results and Updates Outlook

August 6 at 4:05 PM | businesswire.com

Warrior Met Coal Updates Bylaws for Shareholder Clarity

August 6 at 2:36 AM | theglobeandmail.com

TD Asset Management Inc Raises Stock Position in Warrior Met Coal (NYSE:HCC)

August 3, 2025 | marketbeat.com

SunCoke Energy (NYSE:SXC) vs. Warrior Met Coal (NYSE:HCC) Financial Review

August 1, 2025 | americanbankingnews.com

Foster & Motley Inc. Invests $373,000 in Warrior Met Coal (NYSE:HCC)

August 1, 2025 | marketbeat.com

HCC - Warrior Met Coal Inc Key Metrics | Morningstar

July 31, 2025 | morningstar.comM

Warrior Met Coal (HCC) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Warrior Met Coal (NYSE:HCC) Plans $0.08 Quarterly Dividend

July 30, 2025 | marketbeat.com

Analysts Estimate Warrior Met Coal (HCC) to Report a Decline in Earnings: What to Look Out for

July 30, 2025 | zacks.com

Warrior Announces Regular Quarterly Cash Dividend

July 29, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERE, CNR, CNX, and HCC Company Descriptions

Cerevel Therapeutics NASDAQ:CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Core Natural Resources NYSE:CNR

$76.14 +0.21 (+0.28%)

As of 08/8/2025 03:59 PM Eastern

Core Natural Resources, Inc., together with its subsidiaries, produces and sells bituminous coal in the United States and internationally. It operates through two segments, Pennsylvania Mining Complex (PAMC) and CONSOL Marine Terminal. The company's PAMC segment engages in the mining, preparing, and marketing of bituminous coal to power generators, industrial end-users, and metallurgical end-users. This segment includes the Bailey Mine, the Enlow Fork Mine, the Harvey Mine, and the central preparation plant. Its CONSOL Marine Terminal segment provides coal export terminal services through the Port of Baltimore. The company also develops and operates the Itmann Mining Complex located in Wyoming County, West Virginia; and Greenfield Reserves and Resources located in the Northern Appalachian, Central Appalachian, and Illinois basins. The company was formerly known as CONSOL Energy Inc. and changed its name to Core Natural Resources, Inc. in January 2025. Core Natural Resources, Inc. was founded in 1864 and is headquartered in Canonsburg, Pennsylvania.

CNX Resources NYSE:CNX

$29.08 +0.02 (+0.07%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$28.63 -0.45 (-1.55%)

As of 08/8/2025 07:15 PM Eastern

CNX Resources Corporation, an independent natural gas and midstream company, engages in the acquisition, exploration, development, and production of natural gas properties in the Appalachian Basin. The company operates in two segments, Shale and Coalbed Methane (CBM). It produces and sells pipeline quality natural gas primarily for gas wholesalers. The company owns rights to extract natural gas from shale properties in Pennsylvania, West Virginia, and Ohio, as well as rights to extract natural gas from other shale and shallow oil and gas formations in Illinois, Indiana, New York, and Virginia. It also owns rights to extract CBM in Virginia, West Virginia, Pennsylvania, Ohio, Illinois, Indiana, and New Mexico. In addition, the company designs, builds, and operates natural gas gathering systems to move gas from the wellhead to interstate pipelines or other local sales points; owns and operates approximately 2,600 miles of natural gas gathering pipelines, as well as various natural gas processing facilities. It also offers turn-key solutions for water sourcing, delivery, and disposal for its natural gas operations and for third parties. The company was formerly known as CONSOL Energy Inc. and changed its name to CNX Resources Corporation in November 2017. CNX Resources Corporation was founded in 1860 and is headquartered in Canonsburg, Pennsylvania.

Warrior Met Coal NYSE:HCC

$60.72 +1.04 (+1.74%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$60.39 -0.33 (-0.54%)

As of 08/8/2025 07:05 PM Eastern

Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time